Why Interest Rate Rises Won’t Hurt High-Yield Shares

High-yield shares such as GlaxoSmithKline plc (LON: GSK) and Imperial Tobacco PLC (LON: IMT) are unlikely to be hit hard.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Graph showing the FTSE 100 index and FTSE 100 dividend points from October 1999 to October 2013Bank of England Governor, Mark Carney, surprised many investors with his Mansion House speech, where he hinted that interest rates could go up as soon as this year. Indeed, many investors had expected him to wait until after the General Election in 2015 before increasing rates from their historic lows of 0.5%.

In terms of the effect on the stock market, a rise is usually not good news. That’s because (in theory) there is less incentive to invest versus save and it could be argued that high-dividend-paying shares such as GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and Imperial Tobacco (LSE: IMT) could be hit harder as demand for a higher yield declines. However, that may not hold true over the next few years. Here’s why.

High Yields Will Still Be High Yields

Partly as a result of interest rate rises starting from such a low base (a historical low of 0.5%), they will have to increase by a very high multiple before they begin to look attractive to investors. In other words, a 1% rate of interest may be twice as attractive as 0.5%, but is still below inflation and therefore very unattractive. As such, even if interest rates are doubled, trebled or quadrupled, they may not cause a vast number of investors to suddenly sell shares in GlaxoSmithKline and Imperial Tobacco and instead open savings accounts.

Furthermore, the rate at which interest rates are likely to rise may be somewhat pedestrian. In other words, the credit crunch is a very recent memory for the Bank of England and it may be unwilling to take a gamble on choking the UK’s current economic recovery. As a result, interest rates are unlikely to swiftly move the 5%+ level that was in place prior to the credit crunch, meaning high yielding shares are likely to remain attractive over the medium term.

Two High-Yielding Shares With Strong Prospects

When it comes to high yields, they don’t come much higher at present than GlaxoSmithKline and Imperial Tobacco. Both companies are in the top 15 highest-yielding FTSE 100 companies and currently offer yields of 4.8% and 4.4% respectively. Furthermore, dividends are well covered and are set to increase at an attractive pace in the coming years, thereby helping investors in the two companies to stay one step ahead of interest rate rises (whenever they may eventually come).

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

If I’d invested £5,000 in a Nasdaq index fund 5 years ago, here’s how much I’d have now

The Nasdaq index keeps hitting new all-time records in 2024, as US tech stocks fly. How much could I have…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

£500 to invest a month? Consider aiming to turn that into a £20,000 passive income like this!

With a regular monthly investment, it's possible to build a large and steady passive income for retirement. Royston Wild explains.

Read more »

Senior Couple Walking With Pet Bulldog In Countryside
Investing Articles

As retirement needs soar 60%, here’s how I’m building wealth with UK shares

A regular investment in UK shares and funds could help Brits create a large and lasting pension. Our writer Royston…

Read more »

Investing Articles

I’d buy Games Workshop shares before they reach the FTSE 100!

Games Workshop shares look likely to join the FTSE 100 soon. Here’s why I think investors should consider buying the…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Could me buying this stock with a $2.5bn market-cap be like investing in Tesla in 2010?

Archer Aviation (NASDAQ:ACHR) stock's nearly doubled so far in November. Could this start-up be another Tesla in the making?

Read more »

Investing Articles

5,000 shares of this UK dividend stock could net me £1,700 a month in passive income

Our writer calculates the passive income he could earn from holding a significant number of shares in this powerful dividend-paying…

Read more »

Investing Articles

9.3%+ yields! 3 FTSE 100 dividend giants to consider buying

Our writer examines a trio of high-yield FTSE 100 shares and explains some of the opportunities and risks he sees…

Read more »

Investing Articles

As the Kingfisher share price drops on Budget fallout, should I buy?

The Kingfisher share price was on a strong 2024 run until the DIY group warned us of the possible effects…

Read more »